Herberts, Cameron http://orcid.org/0000-0002-9929-8374
Annala, Matti
Sipola, Joonatan http://orcid.org/0000-0003-1438-9988
Ng, Sarah W. S. http://orcid.org/0000-0002-7647-6940
Chen, Xinyi E. http://orcid.org/0000-0001-6125-3253
Nurminen, Anssi http://orcid.org/0000-0002-0057-953X
Korhonen, Olga V.
Munzur, Aslı D.
Beja, Kevin
Schönlau, Elena
Bernales, Cecily Q.
Ritch, Elie
Bacon, Jack V. W.
Lack, Nathan A.
Nykter, Matti
Aggarwal, Rahul http://orcid.org/0000-0001-7003-7982
Small, Eric J. http://orcid.org/0000-0003-3191-6268
Gleave, Martin E.
Quigley, David A.
Feng, Felix Y. http://orcid.org/0000-0002-0963-7687
Chi, Kim N.
Wyatt, Alexander W. http://orcid.org/0000-0003-2399-0329
,
Article History
Received: 13 November 2021
Accepted: 14 June 2022
First Online: 20 July 2022
Competing interests
: M.A. is a shareholder in Fluivia. R.A. has received honoraria from Clovis Oncology and has served in advisory or consulting roles for Dendreon, Advanced Accelerator Applications, Clovis Oncology, Axiom Biotechnologies, AstraZeneca, Pfizer, Merck, Amgen, Jubilant Pharmaceuticals and Alessa Therapeutics. R.A. also has research funding from Zenith Epigenetics, Novartis, Xynomic Pharma, Cancer Targeted Technology, Janssen, Merck, Abbvie, Amgen, AstraZeneca and BioXCel Therapeutics. E.J.S. has stock in Fortis, Harpoon and Teon, and has received honoraria for speaking engagements for Janssen and Johnson & Johnson. E.J.S. has also served in compensated advisory or consulting roles for Janssen, Fortis, Teon and Ultragenyx. M.E.G. is the founder of OncoGenex Technologies, Sustained Therapeutics and Sitka Pharmaceuticals, and has consulted for Astellas, AstraZeneca, Bayer, Janssen, Sanofi, Pfizer, Tersera, Roche and Genova Diagnostics. D.A.Q. has consulted for Varian and Circle Pharmaceuticals. F.Y.F. has served as a consultant or advisory board member for Janssen, Celgene, Blue Earth Diagnostics, Astellas, Myovant, Roivant, Bayer, Novartis and Foundation Medicine, has stock options in Artera and has stock options and is a scientific advisory board member for SerImmune and BlueStar Genomics. K.N.C. has research funding from Janssen, Astellas and Sanofi. K.N.C. also reports research funding and personal fees from Janssen, Astellas, AstraZeneca and Sanofi, as well as personal fees from Constellation Pharmaceuticals, Daiichi Sankyo, Merck, Novartis, Pfizer, Point Biopharma and Roche outside the submitted work. A.W.W. has served on advisory boards and/or received honoraria from AstraZeneca, Astellas, Janssen, and Merck. The laboratory of A.W.W. has a contract research agreement with ESSA Pharma. C.H., J.S., S.W.S.N., X.E.C., A.N., O.V.K., A.D.M., K.B., E.S., C.Q.B., E.R., J.V.W.B., N.A.L. and M.N. declare no competing interests.